You have 5 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bcma

Showing 51 - 75 of 261
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

Recruiting
  • Multiple Myeloma in Relapse
  • BCMA/GPRC5D double CAR-T
  • Shenzhen, Guangdong, China
    Shenzhen Qianhai Shekou Free Trade Zone Hospital
Sep 28, 2023

Multiple Myeloma Trial in Spain (REGN5458, Daratumumab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Athens, Greece
  • +8 more
Nov 30, 2022

Multiple Myeloma Trial in Hefei, Changzhou, Nanjing (Fully human BCMA chimeric antigen receptor autologous T cell injection

Not yet recruiting
  • Multiple Myeloma
  • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
  • Hefei, Anhui, China
  • +3 more
Jan 3, 2022

Multiple Myeloma Trial in Tianjin (Autologous hematopoietic stem cell transplantation, C-CAR088)

Recruiting
  • Multiple Myeloma
  • Autologous hematopoietic stem cell transplantation
  • C-CAR088
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 21, 2022

Systemic Lupus Erythematosus, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Systemic Lupus Erythematosus
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
Aug 31, 2021

Multiple Myeloma Trial in United States (P-BCMA-101 CAR-T cells, Rimiducid)

Terminated
  • Multiple Myeloma
  • Gilbert, Arizona
  • +15 more
May 17, 2022

POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

Active, not recruiting
  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome
  • anti-CD19/BCMA CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 5, 2021

Multiple Myeloma, Tumor, Plasma Cell, Multiple Myeloma in Relapse Trial in Kunming (BCMA targeted prime CAR-T cells)

Recruiting
  • Multiple Myeloma
  • +2 more
  • BCMA targeted prime CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
Jul 30, 2021

Adult Patients Treated in Study R5459-RT-1944 Who Receive A

Not yet recruiting
  • Chronic Kidney Disease (CKD)
  • Noninterventional
  • (no location specified)
Nov 21, 2022

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jul 23, 2022

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, Selinexor-VRD)

Recruiting
  • Multiple Myeloma
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 12, 2023

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

Multiple Myeloma Trial in Hangzhou (BCMA CAR-T cells injection)

Recruiting
  • Multiple Myeloma
  • BCMA CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 13, 2023

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jun 13, 2021

Multiple Myeloma Trial in Shanghai (Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Anti-BCMA CAR-T cells
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 29, 2021

Multiple Myeloma Trial in Nashville (Cevostamab, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Nashville, Tennessee
    Tennessee Onc., PLLC - SCRI
Sep 8, 2022

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 13, 2023

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 1, 2023

Multiple Myeloma Trial in Suzhou (clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells)

Recruiting
  • Multiple Myeloma
  • clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 22, 2021

Relapsed/Refractory Multiple Myeloma Trial in United States (genetic, biological, drug)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ALLO-605
  • +3 more
  • Denver, Colorado
  • +3 more
Feb 9, 2022

Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)

Recruiting
  • Refractory Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • Milwaukee, Wisconsin
    Froedtert & the Medical College of Wisconsin
Aug 3, 2022

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023